<DOC>
	<DOCNO>NCT00696449</DOCNO>
	<brief_summary>The primary objective study investigate potential difference four treatment intervention group adherence treatment Differin® Gel , 0.1 % . Differin approve Food Drug Administration ( FDA ) treat acne .</brief_summary>
	<brief_title>Analysis Adherence Subjects Undergoing Differin Gel , 0.1 % Treatment Moderate Severe Acne Vulgaris</brief_title>
	<detailed_description>Subjects enrol randomized 1:1:1:1 ratio one four treatment intervention group . All Subjects treat once-daily 12 week Differin® Gel , 0.1 % . The four intervention group designate accord follow-up strategy follow : - More frequent normal office visit - Electronic reminder ( voice , e-mail , text message ) - Parental involvement/intervention reminder - No intervention reminder</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<criteria>Male female Subjects race , age 13 18 year inclusive , Subjects diagnosis moderate severe Acne vulgaris , measure lesion count minimum 15 maximum 50 inflammatory lesion ( papule pustule ) face , AND minimum 30 maximum 125 total lesion . Subjects nodule may participate study . Female Subjects childbearing potential must negative urine pregnancy test ( UPT ) . Female Subjects childbearing potential must practice highly effective method contraception study Subjects ( parent/guardian Subject 18 year age ) must willing capable follow study instruction extent degree require protocol ; Subjects able follow study instruction likely complete require visit ; Subjects/Representative sign Informed Consent prior study procedure . Subjects age 18 must one parent guardian read sign Informed Assent Form prior receive study treatment parent ( ) guardian require attend followup visit unless request ; Subject must willing photographed sign release form allow photograph use . Female Subjects pregnant , nurse plan pregnancy study , Subjects condition situation , Investigator 's opinion , may put Subject risk , may confound study result , may interfere Subject 's participation study , Subjects know allergy one component test product , Subjects participate another investigational drug device research study within 30 day enrolment , Subjects acne conglobata , acne fulminans , secondary acne ( chloracne , druginduced acne , etc . ) , severe acne require topical treatment ( e.g . oral isotretinoin ) ; Subjects beard facial hair might interfere study assessment ; Subjects underlying disease dermatological condition require use interfering topical systemic therapy , limited , atopic dermatitis , perioral dermatitis rosacea ; Subjects risk term precaution , warning , contraindication ( see package insert Differin Gel , 0.1 % ) ; Subjects foresee intensive UV exposure study ( mountain sport , UV radiation , sunbathe , etc . ) ; Subjects known history drug and/or alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>